Übersichtsarbeit


Durch Adjuvantien induziertes Autoimmun-Entzündungssyndrom

The development of autoimmune syndrome induced by adjuvants

Keywords | Summary | Correspondence | Literature

Keywords

, , , , , ,

Schlüsselworte

, , , , , ,

Summary

Despite the improvement of materials used in cosmetology, they continue to maintain their immunogenicity. As a result, there is a risk of developing inflammatory responses of cross-reactivity, similar to manifestations of autoimmune inflammatory diseases of connective tissue. We present an overview of recent data and our clinical report about this problem.

Zusammenfassung

Trotz der Verbesserung der in der Ästhetik verwendeten Materialien behalten sie ihre Immunogenität. Dadurch besteht die Gefahr, dass entzündliche Reaktionen der Kreuzreaktivität auftreten, ähnlich wie bei Autoimmunerkrankungen des Bindegewebes. Wir geben einen Überblick über die jüngsten Daten und unseren klinischen Bericht zu diesem Problem.

Leider haben Sie sich nicht eingeloggt, um den Beitrag lesen zu können. Bitte loggen Sie sich ein oder beantragen Sie Ihre Zugangsberechtigung. Vielen Dank. Weitere Informationen finden Sie hier>

Korrespondenz-Adresse

Irina Nikolaevna Goleshchikhina, M.D.
Pacific State Medical University
Prospekt Ostryakova, 2
Vladivostok, Primorskiy kray
RU-690002

Conflict of Interests

Interessenkonflikte: keine

Literatur

1. Agmon-Levin N, Hughes GRV, Shoenfeld Y (2012) The spectrum of ASIA: autoimmune (auto-inflammatory) syndrome induced by adjuvants. p 3-5.
2. Alijotas-Reig J, Garcia-Gimenez V (2008) Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, longterm follow-up and review of the literature. JEADV 22: 150–161.
3. Alster TS, West TB (2001) Human-derived and new synthetic injectable materials for soft-tissue augmentation: current status and role in cosmetic surgery. Plast Reconstr Surg 105: 2515–2525.
4. Andre P, Lowe NJ, Parc A, Clerici TH, Zimmermann U (2005) Adverse reactions to dermal fillers: a review of european experiences. J Cosmet Laser Ther 7: 171–176.
5. Bergeret-Galley C (2004) Comparison of resorbable soft tissue fillers. Aesthetic Surg J 24: 33–46.
6. Bomford M (1989) Adjuvants biotechnology of cells animals. 2: 264-280.
7. Cabral AR, Alcocer-Varela J, Orozco-Topete R, Reyes E, Fernández Domínguez L, Alarcón-Segovia D (1994) Clinical, histopathological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. Rev. Invest. Clin. 46(4): 257–266.
8. Cerpa-Cruz S. et al. (2013) Adverse events following immunization with vaccines containing adjuvants. Immunologic research. 56(2-3): 299-303.
9. Cohen AD, Shoenfeld Y (1996) Vaccine-induced autoimmunity. J Autoimmun 9: 699-703.
10. De Boulle K (2004) Management of complications after implantation of fillers. J Cosmet Dermatol 3: 2–15.
11. De Carvalho JF, Pereira RM, Shoenfeld Y. (2009) The mosaic of autoimmunity: the role of environmental factors. Front Biosci 1: 501-9.
12. Demento SL, Eisenbarth SC, Foellmer HG et al. (2009) Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. 27(23): 3013–3021.
13. Duffy DM (2005) Complications of fillers: overview. Dermatol Surg 31: 1626–1633.
14. Eisenbarth SC. et al. (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198): 1122.
15. Eymann R, Kim YJ, Bohle RM et al. (2012) Microstructural alterations of silicone catheters in an animal experiment: histopathology and SEM findings. Acta Neurochir. Suppl. 113: 87–90.
16. Hajdu SD, Agmon-Levin N, Shoenfeld Y (2011) Silicone and autoimmunity. Eur J Clin Invest. 41: 203-211.
17. Hansen C, Otto E, Kuhlemann K, Förster G, Kahaly GJ (1996) Glycosaminoglycans in autoimmunity. Clinical and Experimental Rheumatology 14(15): 59-67.
18. Israel E, Agmon-Levin N, Blank M, Shoenfeld Y. (2009) Adjuvants and autoimmunity. Lupus 18: 1217-25. 19. Israel E, Agmon-Levin N, Blank M and Shoenfeld Y (2011) Macrophagic myofaciitis a vaccine (alum) autoimmune related disease. CRAI 14: 187-9.
20. Javierre BM, Hernando H, Ballestar E. (2012) Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med 12(68): 535–545.
21. Kivity S et al. (2012) Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: morphea following silicone implantation. Lupus 21(2): 136-139.
22. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1997) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122(2): 265–268.
23. O’Hanlon T, Koneru B, Bayat E et al. (1997) Environmental Myositis Study Group. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum 50(11): 3646–3650.
24. Rev Bras Reumatol (2010). Revista Instituto Medicina Tropical de São Paulo 50(5): 44-51.
25. Shoenfeld Y, Agmon-Levin N (2011) ‘ASIA’–autoimmune/inflammatory syndrome induced by adjuvants. Journal of autoimmunity 36 (1)14-8.
26. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y et al. (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. Isr Med Assoc J 10: 8-12.
27. Simbirtsev NN (2004) Clinical application of cytokines preparation. Immunology 4: 247-251.
28. Tervaert JWC., Kappel RM (2013) Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld’s syndrome). Immunologic research 56(2-3): 293-298.
29. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P et al. (2012) Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld’s syndrome). Lupus 21(2): 128–135.
30. Zafrir Y et al. (2012) Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’(ASIA): analysis of 93 cases. Lupus 21(2): 146-152.

Ausgabe